| Similar Articles |
|---|
 |
The Motley Fool
September 28, 2006
Jack Uldrich |
Is CuraGen Hiding a Genomic Gem? A majority ownership stake in 454 Life Sciences could pay hefty dividends.   |
Chemistry World
January 28, 2015
Rebecca Trager |
Roche chases bolt-on acquisitions as it pushes into genomics A recent spending spree by Roche is intended to take advantage of emerging molecular information and genomic analysis, as the company anticipates that the field will play an increasingly important role for future medicines and diagnostics. |
The Motley Fool
March 30, 2007
Ralph Casale |
Another Genetic Sequencer Gobbled Up Roche buys out second-generation sequencer 454 Life Sciences. Investors, take note. |
Chemistry World
January 27, 2012
Sarah Houlton |
Illumina fends off Roche hostile bid Roche has made a $5.7 billion hostile bid for the genome sequencing company Illumina, after the San Diego, US-based company rejected its initial approach. |
Chemistry World
April 19, 2013
Sarah Houlton |
Thermo Fisher to buy Life Technologies in $15.8bn deal Life Technologies specializes in research products, with a particular focus on genetic sequencing and DNA analysis. |
The Motley Fool
October 5, 2010
Brian Orelli |
You Should Have Seen this FDA Rejection Coming This hepatitis C treatment was marked for failure. |
Science News
December 15, 2007 |
Science Safari: My DNA Project A new website to help people become comfortable with genome issues and learn how to take advantage of the discoveries made possible by the Human Genome Project. |
Bio-IT World
May 19, 2004
Barbara Depompa |
Turning Sugar into Science The landmark building that housed the New England Confectionery Company in Revere, Mass. is being transformed into the new headquarters for the Novartis Institutes for BioMedical Research. |
Bio-IT World
February 2007 |
Bio*IT World's Coming Attractions 2007 Bio-IT World Conference & Expo preview -- Meet the Keynotes... Oracle Users... Systems are Go... Candid Camera... A Vital IT Alliance... Next Generation Informatics... etc. |
The Motley Fool
July 21, 2008
Brian Lawler |
Roche Wants to Buy Genentech -- Again In what could become one of the biggest biotech deals ever, Roche announces that it is offering to pay $43.7 billion for the remaining Genentech shares it doesn't already own. |
Chemistry World
May 29, 2014
Hepeng Jia |
Chinese-made DNA sequencer aims to challenge foreign dominance With an independently developed next-generation DNA sequencer, Chinese scientists are aiming to challenge the dominance of international players in the world's fastest growing genome sequencing market. |
The Motley Fool
August 22, 2007
Brian Orelli |
Yes? No? Maybe So? Roche is still after Ventana. While longtime investors are happy that Roche pointed out Ventana's undervaluation to the rest of the world, current investors think Roche's offer is still too low. |
Chemistry World
August 29, 2014
Sarah Houlton |
Roche to buy InterMune for respiratory boost Roche is to acquire InterMune in a deal worth $8.3 billion. |
Bio-IT World
November 14, 2003
Julia Boguslavsky |
Genome Center in a Box Scientists at 454 Life Sciences developed an integrated end-to-end instrument that performs hundreds of thousands of reactions in parallel -- from sample preparation, amplification, and sequencing to data storage and bioinformatics. |
BusinessWeek
October 1, 2007
Conrad Wilson |
A Dream Team Of Drugs And Diagnosis? If a deal is struck, a Roche-Ventana team could help launch a medical revolution. |
The Motley Fool
October 23, 2009
Brian Orelli |
Swine Flu Doesn't Need to Save Novartis The company is looking healthy all on its own. |
The Motley Fool
May 11, 2006
Brian Gorman |
Albany Molecular Stabilizes The chemistry services company's results are still slumping, but the worst appears to be over. Investors, take note. |
BusinessWeek
November 25, 2009
Arlene Weintraub |
Can Roche Leave Genentech Alone? Now that Roche has acquired the biotech superstar, success will depend on keeping some distance. |
The Motley Fool
August 18, 2010
Luke Timmerman |
Life Technologies Competes for Cheap DNA Sequencing In the race to cheaper gene sequencing. |
The Motley Fool
March 17, 2011
Brian Orelli |
Eat or Be Eaten? Perhaps Both. Oft-rumored takeout target Human Genome Sciences goes shopping. |
Chemistry World
September 2006
Yfke Hager |
Careers: Analytical Expertise After years of jumping between chemistry jobs, Adam Hold created his dream career by setting up his own company to provide analytical services. |
The Motley Fool
February 28, 2008
Brian Lawler |
Third Wave Making Tiny Ripples Small molecular-diagnostics developer Third Wave Technologies could be poised for big returns. |
The Motley Fool
July 20, 2005
Stephen D. Simpson |
Two Ways to Play Roche Trying to track Roche is a pain, so investors might want to think about Genentech instead. |
IEEE Spectrum
March 2013
Susan Hassler |
Genome to Go It's already possible to have your own genome sequenced. But personalized medicine based on sequencing still has a way to go |
The Motley Fool
August 14, 2008
Brian Lawler |
Genentech Asks Roche to Pay Up In one of the more friendly spurnings of a buyout offer in recent months, Genentech calls Roche's $89-per-share buyout offer too low, and very nicely implies that Roche should up its bid. |
Chemistry World
January 4, 2007
Richard Van Noorden |
Knighthood for Services to Chemistry Fraser Stoddart, director of the California NanoSystems Institute and professor of NanoSystems Sciences at the University of California, has been appointed a Knight Bachelor for his services to chemistry and molecular nanotechnology. |
Chemistry World
June 12, 2014
Emma Stoye |
China launches nationwide proteome project China has officially launched the China Human Proteome Project, a nationwide effort to map all the proteins in major organs over the next three to five years. |
Bio-IT World
July 14, 2004
Davies & Russell |
The Sweet Hereafter Novartis' stunning new research home in a former candy factory is but one ingredient in a bold new recipe for success that embraces leadership, culture, science, and technology. |
CIO
June 1, 2003
Bob Violino |
Powerful DNA Portable computer vendors like to boast about their small and lightweight devices. But their best efforts are nothing compared with programmable molecular computing machines composed of an enzyme and DNA molecules. |
BusinessWeek
July 1, 2010
Doherty & Waters |
Post-Buyout, Genentech's DNA Is Dominant Bought out for $47 billion, the biotech pioneer has gained the upper hand |
Bio-IT World
October 2005
Dennis A. Gilbert |
The DNA Sequencing Race: From Sprint to Marathon To create faster, cheaper, and better solutions for DNA analysis, we must remain committed to improving both current and new sequencing technologies. Research that just a short while ago might have been considered too complex, too expensive, or just inconceivable is now well within our grasp. |
Bio-IT World
October 9, 2002
Kevin Davies |
Cracking the 'Druggable Genome' How many potential drug targets are encoded in the human genome? It is a crucial question for every biopharma business. |
The Motley Fool
October 17, 2006
Brian Lawler |
Roche Rocks The Swiss pharma has a stable of hot brands and lots of promise in the pipeline. Investors, this may be a pharmaceutical worth looking at. |
The Motley Fool
June 7, 2011
Brian Orelli |
Sometimes a Partnership Feels Personal Merck and Roche hook up for a diagnostic drug deal. |
Information Today
March 4, 2013 |
History of Science, Technology and Medicine Now Available from EBSCO Publishing History of Science, Technology and Medicine reflects the influences of the fields of science, technology, and medicine on society and culture from prehistory to the present and offers outstanding value for interdisciplinary research. |
The Motley Fool
February 27, 2009
Brian Orelli |
Waiting to Inhale Human Genome Sciences is guiding for revenue of $250 million this year compared to less than $50 million last year, thanks to its sale of anthrax emergency treatment ABthrax to the government. |
Chemistry World
October 29, 2014
Phillip Broadwith |
CHF3bn redevelopment for Roche's Basel site Swiss pharma major Roche plans to spend CHF3 billion ( 2 billion pounds) over the next 10 years on redeveloping its headquarters in Basel. |
Chemistry World
June 28, 2013
Phillip Broadwith |
Data-sharing partnership for drug discovery AstraZeneca and Roche are pooling their data on compound properties to boost their chances of success in early stage drug development. |
Bio-IT World
September 2005
Kevin Davies |
Fantastic 454: DNA Sequencing Pyrotechnics In an exciting advance for DNA sequencing technology, a research team at 454 Life Sciences Corp. has essentially sequenced and assembled a bacterial genome sequence based on a mere 4-hour run on the company's proprietary instrument. |
Bio-IT World
March 2006 |
Bio-IT World Bio-IT 50 The 50 companies profiled here have driven and continue to drive the future of biomedical research and drug discovery: Accelrys... Affymetrix.. Apple... Becton Dickinson... BlueArc... 454 Life Sciences... etc. |
The Motley Fool
February 25, 2009
Brian Orelli |
Will It Ever End? Genentech's Special Committee of its Board of Directors recommended that investors reject Roche's most recent tender offer. |
